JP2019522039A - 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド - Google Patents

気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド Download PDF

Info

Publication number
JP2019522039A
JP2019522039A JP2019504932A JP2019504932A JP2019522039A JP 2019522039 A JP2019522039 A JP 2019522039A JP 2019504932 A JP2019504932 A JP 2019504932A JP 2019504932 A JP2019504932 A JP 2019504932A JP 2019522039 A JP2019522039 A JP 2019522039A
Authority
JP
Japan
Prior art keywords
patient
carboxamide
oxazepan
ethyl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019504932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522039A5 (https=
Inventor
カルロス・フェルナンデス
ライニルド・ヘイルマン
ユージーン・サリバン
ハンス・ローランド・レン
スティーブン・コノリー
スティーブン・スワロウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2019522039A publication Critical patent/JP2019522039A/ja
Publication of JP2019522039A5 publication Critical patent/JP2019522039A5/ja
Priority to JP2022075836A priority Critical patent/JP2022115951A/ja
Priority to JP2024174121A priority patent/JP2025000959A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504932A 2016-07-29 2017-07-28 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド Pending JP2019522039A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022075836A JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662368400P 2016-07-29 2016-07-29
US62/368,400 2016-07-29
PCT/US2017/044343 WO2018022978A1 (en) 2016-07-29 2017-07-28 Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022075836A Division JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Publications (2)

Publication Number Publication Date
JP2019522039A true JP2019522039A (ja) 2019-08-08
JP2019522039A5 JP2019522039A5 (https=) 2020-08-27

Family

ID=61011892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019504932A Pending JP2019522039A (ja) 2016-07-29 2017-07-28 気管支拡張症の処置のための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
JP2022075836A Pending JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A Pending JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022075836A Pending JP2022115951A (ja) 2016-07-29 2022-05-02 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
JP2024174121A Pending JP2025000959A (ja) 2016-07-29 2024-10-03 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド

Country Status (6)

Country Link
US (6) US20180028541A1 (https=)
EP (1) EP3490566A4 (https=)
JP (3) JP2019522039A (https=)
KR (4) KR20250107292A (https=)
CN (1) CN109789150A (https=)
WO (1) WO2018022978A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
JP7854219B2 (ja) 2022-01-11 2026-05-01 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
US20210252015A1 (en) * 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN116157687A (zh) 2020-07-20 2023-05-23 英斯梅德股份有限公司 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法
US20240150335A1 (en) * 2021-02-05 2024-05-09 Medshine Discovery Inc. Fused ring derivatives containing 1,4-oxazepane
WO2022232420A1 (en) * 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937B (zh) * 2021-12-23 2026-04-10 杭州邦顺制药股份有限公司 二肽基肽酶ⅰ抑制剂及其用途
EP4479059A4 (en) * 2022-02-16 2026-01-28 Insmed Inc CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
JP2026510407A (ja) * 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物
KR102951779B1 (ko) 2023-08-31 2026-04-14 서울대학교병원 비결핵항산균 질환 및 기관지확장증의 진단을 위한 바이오마커 조성물
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases
WO2025250560A1 (en) * 2024-05-28 2025-12-04 Insmed Incorporated Methods for treating bronchiectasis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540526A (ja) * 2007-09-25 2010-12-24 ノバルティス アーゲー エアロゾル化されたバンコマイシンのような薬剤での肺障害の処置
JP2012526093A (ja) * 2009-05-07 2012-10-25 アストラゼネカ・アクチエボラーグ 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
US20150210655A1 (en) * 2014-01-24 2015-07-30 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
WO2015175939A1 (en) * 2014-05-15 2015-11-19 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2016075240A1 (en) * 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
JP2016515576A (ja) * 2013-04-01 2016-05-30 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
KR20250002710A (ko) * 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540526A (ja) * 2007-09-25 2010-12-24 ノバルティス アーゲー エアロゾル化されたバンコマイシンのような薬剤での肺障害の処置
JP2012526093A (ja) * 2009-05-07 2012-10-25 アストラゼネカ・アクチエボラーグ 置換１−シアノエチルヘテロシクリルカルボキサミド化合物７５０
JP2016515576A (ja) * 2013-04-01 2016-05-30 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
US20150210655A1 (en) * 2014-01-24 2015-07-30 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
WO2015175939A1 (en) * 2014-05-15 2015-11-19 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2016075240A1 (en) * 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
JP7854219B2 (ja) 2022-01-11 2026-05-01 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用

Also Published As

Publication number Publication date
US20200179398A1 (en) 2020-06-11
US20180028541A1 (en) 2018-02-01
EP3490566A1 (en) 2019-06-05
KR20190035781A (ko) 2019-04-03
CN109789150A (zh) 2019-05-21
EP3490566A4 (en) 2020-03-11
KR20230054480A (ko) 2023-04-24
US20190091236A1 (en) 2019-03-28
KR20250107292A (ko) 2025-07-11
JP2025000959A (ja) 2025-01-07
KR20240091302A (ko) 2024-06-21
WO2018022978A1 (en) 2018-02-01
US20220133737A1 (en) 2022-05-05
US20240041896A1 (en) 2024-02-08
US20250228870A1 (en) 2025-07-17
JP2022115951A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP2025000959A (ja) 気管支拡張症の処置のための特定の（２ｓ）－ｎ－［（１ｓ）－１－シアノ－２－フェニルエチル］－１，４－オキサゼパン－２－カルボキサミド
US11975005B2 (en) Treatment of respiratory diseases
CA3089240A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
US20240226112A1 (en) Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
US20220281846A1 (en) Compounds and compositions for the treatment of respiratory diseases
CA3186844A1 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
EP3188759B1 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
WO2025250560A1 (en) Methods for treating bronchiectasis
EP4501326A1 (en) Therapeutic agent for respiratory disease
HK40036810A (en) Method of treatment and compositions comprising a dual pl3k delta-gamma kinase inhibitor and a corticosteroid
HK40058742B (zh) 呼吸性疾病的治疗
HK1240503B (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
HK1240503A1 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220105

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220502

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220531

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220531